Method for diagnosing neoplasms
Disclosed are uses of Gangliosides G M1 and/or asialo-G M1 substances simulating the carbohydrate portion of said gangliosides with regard to bonding to anti-G M1 antibodies and/or anti-AD M1 antibodies for producing agents which bind or block anti-G M1 antibodies and/or anti-AG M1 antibodies which bond to natural killer cells (NKC) or for blocking antigen-presenting cells and producing a T-cell anergy, and for producing an affinity material for the extracorporeal removal of anti-G M1 antibodies and/or anti-AG M1 antibodies in order to prevent, inhibit, and treat malignant cancers.
1. A method for the early diagnosis of cancer in a patient, said method comprising determining the amount of anti-asialoG M1 (AG M1 ) antibodies of the IgG and/or IgA type in a biological sample from a patient in whom cancer is suspected wherein said cancer is selected from the group comprising a carcinoma of the colon, a carcinoma of the breast, an ovarian carcinoma, a carcinoma of the pancreas, a carcinoma of the oesophagus, a carcinoma of the gall bladder, a carcinoma of the liver, a C cell carcinoma, a carcinoma of the thyroid, a carcinoma of the prostate, a carcinoma of the lung, a carcinoma of the appendix, a carcinoma of the bladder, a cardiac carcinoma, a carcinoma of the distal oesophagus, a carcinoma of the floor of the mouth, and a carcinoma of the kidney, wherein increased amounts of said antibodies compared with normal persons indicates the presence of cancer.
2. The method of claim 1 , wherein the method is carried out with the aid of an immunoassay of the sandwich type or the competitive type.
3. The method of claim 2 , wherein the immunoassay uses a reagent labeled with a chemiluminescence molecule.